Most interestingly, constitutive WNT/β-catenin activation had negative effects both on the disease control rate and progression-free survival (PFS) of HCC patients who received anti-PD1 therapies [32,33]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.